ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle
BUZZ-ARS Pharma tumbles as allergy nasal spray faces insurance coverage hurdle ** Shares of ARS Pharmaceuticals SPRY.O fall 26% to $7.79, snapping a three-day gaining streak
** ARS Pharmaceuticals said late on Wednesday it did not get any new insurance coverage approvals for its allergy spray neffy in the latest July cycle
** Neffy is an epinephrine nasal spray used for emergency treatment of severe allergic reactions, and it is already approved for use in adults and children above a certain weight
** The company cut its 2026 spending forecast to about $248 million as it tightens costs
** It still expects neffy sales growth to help reach cash-flow breakeven in 2027
** "While we expect this news to be viewed somewhat negatively given investor expectations for a favorable CVS CVS.N Caremark coverage decision catalyst, we think the long-term value for neffy remains largely intact, and we remain positive on the story," Leerink Partners analyst says
** The drug remains widely available to commercially insured patients through existing coverage and a retail cash option priced in line with other epinephrine products
** As of last close, stock down 9.5% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on CVS Health
See all newsHealth Rounds: GLP-1 drugs tied to heart improvements in patients with obesity and heart failure
US health insurers fall for third day on CMS audit proposal, Medicare-for-All concerns
Health insurers extend decline on proposed new rule to curb fraud
Health insurers extend decline on proposed new rule to curb fraud
UnitedHealthcare to expand program paying pharmacists for medical services